Novo Nordisk has discontinued its small molecule research in an effort to focus on biopharmaceutical research and its protein-based pharmaceuticals. The decision will affect approximately 180 employees, half of which the company plans to offer other positions. Since 2002, the company has been increasing its focus on therapeutic proteins and its pipeline of protein-based pharmaceuticals within diabetes, haemostasis, growth disorders and other diseases. “Our core competences lie w...